Alnylam Pharmaceuticals | ALNY - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Incyte USD 582K 13K 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 281M 8M 2025-09
PTC Therapeutics USD 3.25B 381.37M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 21.51M 205K 2026-06
Takeda JPY 63.85B 20.2B 2026-06
Tectonic Therapeutic USD 246.58M 246.56M 2026-03
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 7.35M 2.65M 2026-06